首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   71039篇
  免费   7420篇
  国内免费   4812篇
耳鼻咽喉   592篇
儿科学   1080篇
妇产科学   299篇
基础医学   4993篇
口腔科学   1206篇
临床医学   8486篇
内科学   7037篇
皮肤病学   771篇
神经病学   2229篇
特种医学   3127篇
外国民族医学   11篇
外科学   8075篇
综合类   18617篇
现状与发展   21篇
预防医学   7331篇
眼科学   824篇
药学   8198篇
  90篇
中国医学   6217篇
肿瘤学   4067篇
  2024年   197篇
  2023年   890篇
  2022年   2144篇
  2021年   3049篇
  2020年   2578篇
  2019年   1582篇
  2018年   1705篇
  2017年   2124篇
  2016年   1681篇
  2015年   3054篇
  2014年   3933篇
  2013年   4507篇
  2012年   6591篇
  2011年   7200篇
  2010年   6008篇
  2009年   5297篇
  2008年   5663篇
  2007年   5373篇
  2006年   4559篇
  2005年   3743篇
  2004年   2685篇
  2003年   2346篇
  2002年   1806篇
  2001年   1490篇
  2000年   1199篇
  1999年   633篇
  1998年   202篇
  1997年   226篇
  1996年   181篇
  1995年   148篇
  1994年   141篇
  1993年   74篇
  1992年   53篇
  1991年   52篇
  1990年   33篇
  1989年   23篇
  1988年   24篇
  1987年   23篇
  1986年   24篇
  1985年   7篇
  1984年   4篇
  1983年   5篇
  1982年   5篇
  1981年   2篇
  1979年   1篇
  1963年   1篇
  1959年   1篇
  1958年   1篇
  1957年   1篇
  1954年   1篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
芦沙坦和苯那普利对高血压大鼠左室肥厚的抑制作用   总被引:2,自引:0,他引:2  
目的:研究芦沙坦及苯那普利对老龄前期自发性高血压大鼠(SHR)左室肥厚及丝裂素活化蛋白激酶(MAPK)的抑制作用。方法:将老龄前期SHR随机分为SHR对照组,苯那普利(10mg.kg^-1.d^-1)及芦沙坦(30mg.kg^-1.d^-1)治疗组,治疗期为3个月,每月测压一次,治疗结束后处死动物,测定心肌肥厚指标、血中及心肌中内皮素(ET)、血管紧张素AⅡ及MAPK。结果:苯那普利及芦沙治疗后血压、心肌肥厚指标、血中及心肌中内皮素(ET)及MAPK明显低于SHR相对照组(P<0.01),芦沙坦组血中及心肌中AⅡ无下降。结论:AⅡ、ET及MAPK参与了SHR的血压升高及心肌肥厚的形成。苯那普利及芦沙坦有抑制AⅡ、ET及MAPK的活性,从而达到降压及逆转心肌肥厚的作用。  相似文献   
62.
63.
目的评价紫杉醇洗脱冠状动脉支架(TAXUStmBoston公司产品)应用于急性冠状动脉综合症病人的临床疗效及安全性。方法自2003年5月至2004年12月接受TAXUS支架治疗的94例急性冠状动脉综合症患者,观察术后即刻效果、术后6个月心脏性死亡、心肌梗塞、再次血管重建及冠状动脉造影复查情况。病例中包括ST段抬高的急性心肌梗塞27例,非ST段抬高的急性心肌梗死8例,不稳定心绞痛59例。结果支架植入成功率为99%,术中和随访期间无死亡,术后1例出现亚急性血栓,1例晚期血栓致心肌梗塞,另有5例随访中进行了血管重建术,6个月主要心脏不良事件(MACE)发生率7.4%。术后6~7个月23例的冠状动脉造影复查再狭窄率为13.0%(支架内为8.6%),靶病变重建率为2.7%。结论应用TAXUS支架治疗急性冠状动脉综合症是安全和有效的,支架内再狭窄率明显低于普通金属支架。  相似文献   
64.
组织多肽特异性抗原在原发性肝癌中的临床应用   总被引:2,自引:0,他引:2  
OBJECTIVE: To evaluate the clinical value of serum tissue polypeptide specific antigen (TPS) for primary hepatic cancer in comparison with alpha-fetoprotein (AFP). METHODS: TPS and AFP were measured by enzyme-linked immunosorbent assay (ELISA) in 85 patients with primary hepatic cancer, 19 with metastatic hepatic cancer, 35 with liver cirrhosis, 22 with chronic hepatitis and 50 healthy control subjects. RESULTS: Serum AFP levels were elevated in patients with hepatocellular carcinoma in comparison with that in cholangiocarcinoma patients (P=0.037), but the difference was not significant (P=0.737). Serum TPS levels were significantly correlated with the tumor size (P=0.001), but not with the number of the tumors, portal invasion, extrahepatic metastasis, clinical stage or histological differentiation (P>0.05). A significant correlation was observed between AFP level and tumor size (P=0.028), portal invasion(P=0.005), and histological differentiation (P=0.000). CONCLUSION: TPS alone offers no more clues than AFP for the diagnosis of primary hepatic cancer, though it can be helpful for the diagnosis of cholangiocarcinoma. It has only limited clinical utility as a marker for primary hepatic cancer.  相似文献   
65.
神经外科麻醉对体感诱发电位的影响   总被引:1,自引:0,他引:1  
目的探讨神经外科手术麻醉对体感诱发电位(SEP)的影响,以期为麻醉和手术处理提供依据。方法随机抽取我科17例全麻手术病人,分成颅内疾病手术组(A组)与脊柱、脊髓疾病手术组(B组),于术前、麻醉(诱导完成)、术始、术中、术毕和术后6个时程连续监测SEP的潜伏期、波幅及波形并记录。结果麻醉后SEP潜伏期延长5.96%,波幅下降24.00%,未出现波形消失的情况。结论麻醉抑制SEP,表现为潜伏期延长和波幅下降,但未出现波形消失的情况。  相似文献   
66.
目的 探讨齿槽裂修复治疗的目的、方法以及治疗时机的选择。方法 查阅1950年至2006年有关齿槽裂修复的文献,归纳文献中报道的不同方法,并评价其各自的优缺点。结果 齿槽裂修复的主要目的:关闭口鼻瘘;建立稳定、连续的上颌骨牙弓;为牙齿萌出提供基础;为上唇和鼻底提供稳定支架。主要治疗方法:植骨术;牵引成骨技术;组织工程骨和生长因子应用;引导骨再生技术。患者最佳的手术治疗时机是9~11岁时混合牙列期。结论 在9~11岁混合牙列期手术,以髂骨松质骨为移植材料被认为是修复齿槽裂的主要手段。牵引成骨技术、组织工程技术和引导骨再生技术,将是齿槽裂修复的新方向。  相似文献   
67.
目的探讨应用肩胛皮瓣修复不同部位皮肤软组织缺损的方法.方法设计以旋肩胛动脉及其皮支为供血系统的肩胛皮瓣,采用岛状皮瓣、吻合的游离皮瓣及借助知名动脉吻合携带的皮瓣修复头面、腋胸部及四肢皮肤软组织缺损创面.结果临床应用10例患者,皮瓣完全成活,患者局部外形及功能均比较满意.结论肩胛皮瓣的供瓣区较大,血供稳定充足,具有多种形式皮瓣移植的优点,是一种有效的修复皮肤软组织缺损的供瓣区.  相似文献   
68.
Our objective was to develop and evaluate 3 semiautomatic computer-aided diagnostic (CAD) schemes for distinguishing between benign and malignant pulmonary nodules by use of features extracted from CT, 18F-FDG PET, and both CT and 18F-FDG PET. METHODS: We retrospectively collected 92 consecutive cases of pulmonary nodules (<3 cm) in patients who underwent both thoracic CT and whole-body PET/CT. Forty-two of the nodules were malignant and 50 benign, as confirmed by pathologic examination and clinical follow-up. The interval between CT and PET was less than 1 mo. Four clinical parameters, including patient age, sex, smoking status, and history of previous malignancy, were used for the CAD schemes. Sixteen CT features based on size, shape, margin, and internal structure of nodules were independently rated subjectively by 2 chest radiologists. Four PET features were viewed on a PET/CT workstation. CAD schemes based on clinical parameters together with CT features, PET features, and both CT and PET features were then used to differentiate benign from malignant nodules. Finally, the output from the CAD schemes was evaluated by use of receiver-operating-characteristic analysis. RESULTS: When we used clinical parameters and CT features as input units (CAD scheme 1), the area under the receiver-operating-characteristic curve (A(z) value) of the CAD scheme was 0.83. When we used clinical parameters and PET features as input units (CAD scheme 2), the A(z) value for the computer output was 0.91. However, when we used all data as input units (CAD scheme 3), the A(z) value for the computer output was 0.95. The performance of CAD scheme 3 was better than that of CAD scheme 1 or 2. A statistically significant difference existed between the A(z) values of CAD schemes 3 and 2 (P = 0.037) and between those of CAD schemes 3 and 1 (P = 0.015). CONCLUSION: Our CAD scheme based on both PET and CT was better able to differentiate benign from malignant pulmonary nodules than were the CAD schemes based on PET alone and CT alone.  相似文献   
69.
Objective To test the hypothesis that p53 gene therapy combined with endostatin can enhance tumor response to radiation therapy of RM-1 mouse xenograft prostate cancer and to investigate its mechanism. Methods A mouse prostate cancer model was established. Then mice with xenograft tumor were randomly divided into group A (control), B (radiation), C (radiation and rAdp53), D (radiation and rh-endostatin) and E (radiation and rAdp53 and rh-endostatin). On day 1, rAdp53 was injected intra-tumorously with 1 × 1010 vp per animal to group C and E. From day 1 to 14, rh-endostatin was given 15 mg/kg intraperitoneally daily to group D and E. On day 4 single fraction of 15 Gy was given to tumors in groups B, C, D and E. Normal saline was injected intra-tumorously or intraperitoneaUy accordingly as control. No treatment was done to group A. Tumor volume was measured daily. Samples were collected on Days 5, 10 and 15. Ki67, CD31, p53 and VEGF were detected by means of immunohistochemistry. Results (1) Radiation alone, radiation combined with intra-tumorous injection of Adp53 and/or intraperitoneal injection of rh-endostatin resulted in tumor growth arrest of RM-1 cells in vivo (P = 0.000). Radiation combined with both rAdp53 and rh-endostatin was the most effective treatment (P < 0.05). (2) All the four treatment groups had a decreased expression of mutant type P53 (P = 0.000). The expression of Ki67 in groups B and C were equal (P 0.05) and increasing (P = 0.000), respectively. Group D had a up-down-up curve (P < 0.05), but group E had a up-down one. On day 5 the expresion of VEGF in group E was the lowest (P < 0.05). An increased expression of MVD compared with the control was shown, and MVD in groups C, D and E were always higher than that in the control (P < 0.05). Conclusions The limitation of radiotherapy could be overcome by combination with beth p53 gene therapy and endostatin on the growth of mouse prostate cancer cell. Radiation, rAdp53 and endostatin have their own role but they can be interacted with each other.  相似文献   
70.
Aim: We performed a semiprospective and retrospective review of all admissions to a single institution of systemic lupus erythematosus (SLE) patients, admitted due to active disease. The aim was to describe differences in disease activity as a cause of hospital admissions between patients originating from South‐East Asia/China (SAC) and Caucasians. Method: There were 210 patients admitted for active disease, with a total of 567 admissions for active SLE over a 16‐year period. Allowing for patients who had left our database, there was a total of 3415 patient years of observation. Results: Patients from SAC with a flare requiring admission presented earlier in their disease course and with more active disease than did Caucasians (median SLE Disease Activity Index 13 vs. 8, P= 0.002). They had longer inpatient stays (7 vs. 5 days P = 0.03). There was a trend to higher rates of re‐presentation to hospital for flare (59% in SAC patients vs. 41% in Caucasians, P = 0.09) with more subsequent admissions (3 vs. 2 P = 0.06) despite a shorter period of observation. Conclusions: South‐East Asian/Chinese were more likely to be diagnosed with class III/IV glomerulonephritis and require cyclophosphamide both at presentation and subsequent admissions. More patients from SAC were readmitted to hospital for severe central nervous system disease after their first hospital admission. In this population, lupus patients had more severe flares and more frequently required admission for these than Caucasians.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号